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INTRODUCTION 
Menopause is a natural process that occurs in a 
woman’s life as a part of normal aging. Nowadays with 
better lifestyle, better health care facilities and longer 
life span more and more women live well past the age 
of menopause and survive to endure the consequences 
of menopause and it is estimated that by the end of 2015 
there will be 130 million elderly women in India
1,2
.  
 Menopause which is associated with decline in 
estrogen level may adversely affect the life of women. 
Though some women  do not experience any  
menopausal symptoms,  a considerable proportion 
suffer from  wide range of climacteric symptoms like 
hot flushes, night sweats, insomnia, palpitation, 
depression etc. often starting several years before the 
final menstrual period 
3
.  This has a marked negative 
effect on the quality of life and prompts the menopausal 
women to visit health care professionals.  
Systemic hormone replacement therapy (HRT) in the 
form of combination of estrogen and progesterone or 
estrogen alone has been available for over half a century 
for the management of menopausal symptoms. After the  
results of Women’s Health Initiative (WHI) and the 
Heart and Estrogen/ Progestin Replacement Study 
(HERS) which reported an unfavorable balance of risks 
compared with benefits, there was a major shift in 
perspective on HRT  and has  led to a significant 
decline in the use of hormonal treatment 
4,5
. 
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ABSTRACT 
Objective: This study was conducted with the objective of comparing safety and efficacy of hormonal treatment and non-
hormonal alternatives for the management of menopausal symptoms. 
Materials and Methods: A total of 40 patients suffering from menopausal symptoms were recruited to the study protocol and 
were divided into 4 groups according to the treatment they received, with 10 patients in each group. Group A received 
conjugated estrogen and medroxy progesterone acetate, Group B received Tibolone, Group C received Isoflavone and Group D 
received Vitamin E. Efficacy of the treatment was evaluated by improvement in symptomatic score and safety of the treatment 
was assessed on the basis of adverse effects reported and relevant laboratory investigations. 
Results:  Most of the symptoms were significantly improved in groups A and B (p< 0.01) while in groups C and D significant 
improvement was observed in hot flushes, sweating and insomnia (p<0.05). On comparative analysis there was no significant 
difference in the efficacy between groups A and B and between groups C and D. On the other hand significant difference was 
observed in the efficacy when groups A and B were compared with groups C and D (p<0.01). Only mild tolerable side effects 
were reported by the patients in all the groups with slightly higher incidence in groups A and B. 
Conclusions:  Hormonal treatment is very efficacious for the early relief of menopausal symptoms. Isoflavone and vitamin E 
can be considered as a satisfactory treatment alternative when for any reasons hormonal treatment cannot be used.   
Key Words:  HRT, Tibolone , Isoflavone, Menopausal symptoms 
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The constantly changing landscape regarding 
menopausal hormonal therapy has been challenging for 
providers caring for menopausal women. After a decade 
of fear and uncertainty regarding HRT, reanalysis of the 
WHI data and the results of recent studies have 
provided some clarity regarding the balance of risks and 
benefits of systemic menopausal HRT. Age and years 
since menopause are now known to be important 
variables affecting the benefit-risk profile. For 
symptomatic menopausal women who are under 60 
years of age or within 10 years of menopause, the 
benefits of HRT generally outweigh the risks 
6,7
. 
Other hormonal alternative is tibolone, which is a 
synthetic compound with weak hormonal properties, is 
equally effective in relieving menopausal symptoms as 
the conventional HRT but continues to have concerns 
over long term adverse consequences of hormone 
therapy 
8,9
.  
Thus the apprehensions about safety and efficacy of 
hormonal treatments has led to the exploration of a  
number of  non-hormonal alternative treatments like 
isoflavone, vitamin E, Black Cohosh, St. Johns Wort etc 
in perimenopausal and postmenopausal women for the 
control of menopausal symptoms. At present the data 
regarding efficacy and safety of these alternatives  are 
limited, most of the studies are placebo controlled and 
none of the studies has compared  these alternatives 
with the hormonal treatment particularly in Indian 
patients. Therefore, this study was planned to compare 
the efficacy and safety of hormonal and non-hormonal 
alternatives treatments used for the management of 
menopausal symptoms. 
MATERIALS AND METHODS 
This was a prospective observational study conducted in 
the Pharmacology department of Himalayan Institute of 
Medical Sciences, Dehradun over a period of six 
months. Subjects selected were patients attending 
outpatient department of Obstetrics and Gynaecology. 
The protocol was approved by the ethical committee of 
the institute and all study subjects gave their written 
informed consent. Eligibility for enrollment in the study 
was based on inclusion and exclusion criteria. 
Inclusion Criteria 
 Perimenopausal Women 
 Postmenopausal women 
 Surgical menopause 
 Must be experiencing menopausal symptoms  
 Age˂ 60 years 
 Time of enrollment ˂ 10 years since menopause 
 Exclusion Criteria  
 Undiagnosed abnormal vaginal bleeding  
 Women with active thromboembolic disease or 
thrombophlebitis or history of thromboembolic 
disease. 
 Estrogen dependent neoplasm such as those of 
breast or endometrium. 
 Women with active liver disease 
 Sever cardiac disease 
 Diabetes 
Subjects fulfilling inclusion criteria were recruited to 
the study protocol. All women selected were otherwise 
healthy on the basis of routine clinical and laboratory 
examination, except for menopausal sign and 
symptoms. None of them had received any type of 
treatment or therapy for menopausal symptoms in the 
last 6 months before enrollment in the study.  
Total number of 40 patients were enrolled in the study. 
10 women were recruited to each of the following 4 
groups according to the treatment they received.  
Group A received Conjugated estrogen 0.625mg/day for 
25 days and Medroxy Progesterone Acetate (MPA) 
from 16
th
-25
th
 day of the month. Women who were 
hysterectomised did not receive MPA.  
Group B received Tibolone 2.5mg/day. Only those 
patients were enrolled in this group who had 
ammenorrhoea of at least 1year. 
Group C received Isoflovone 75mg/day.  
Group D received Vitamin E 400 mg/day. 
All the drugs were given orally for a period of 3 
months. All study participants were required to make 3 
follow up visits i.e after 1 week, I month and 3 months 
of treatment. Patients were examined on day 0 and at 
each follow up visit. Relevant investigations were done 
on day 0 and after 3 months. After 3 months 
mammography was done only in subjects of group A 
and group B. 
Efficacy of the treatment was assessed by improvement 
in symptomatic score
8
. The symptoms complained by 
the patients were scored on a scale of 0-3 (0= none, 1= 
mild, 2= moderate, 3= severe) which was recorded on 
the day of enrollment (day 0) and at each follow up 
visit. Finally the symptom score at each follow visit was 
compared with the baseline values. 
A check list was used to enquire about adverse effects 
at each visit by the patients. The patients were 
encouraged to describe their symptoms at each visit.  
Statistical Analysis 
The results were analyzed using student t test (paired 
and unpaired) and were expressed as mean ± SE. 
OBSERVATIONS AND RESULTS 
Out of the 40 patients enrolled in the study, 10 were 
perimenopausal and 30 postmenopausal (14 surgical 
and 16 natural menopause). Menopausal status in 
different treatment groups is given in (Table 1). 
Demographic parameters and other baseline 
characteristics were similar in all the 4 groups (table2). 
Mean age of menopause as analyzed from the 16 natural 
menopausal women in the study was 48.06 ± 0.93 
years. Age of onset of menopause shows no relationship 
with education, diet, socioeconomic status, religion, 
menarche age, and OCP use. 
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Table 1: Menopausal status in different treatment groups 
 
 
 
 
 
Table 2: Demographic parameters (mean ± SE) of perimenopausal and postmenopausal women in different treatment 
groups:  
Group Age in 
years 
Religion 
H:M:O 
Edu. 
 
Il:L 
SES 
H:M:L 
Occ. 
W:NW 
Menarche 
Age in yrs 
Parity H/o 
OCP 
use 
Marital 
History in 
years 
Years since 
menopause 
Group A 
(n = 10) 
45.4 ± 
1.70 
7:2:1 2:8 0:10:0 1:9 13.1± 0.28 3.3± 
0.47 
2:8 28.8±2.01 3.5± 0.88 
Group B 
(n = 10) 
51.1 ± 
1.93 
9:1:0 3:7 1:8:1 0:10 13.7± 0.30 3.3± 
0.34 
1:9 32.8±1.44 4.7 ± 0.98 
Group C 
(n = 10) 
45.6 ± 
2.07 
9:1:0 3:7 1:8:1 1:9 13.5± 0.22 3± 
0.62 
1:9 29.4±1.56 5.0 ± 1.54 
Group D 
(n = 10) 
48.2 ± 
1.68 
10:0:0 2:8 0:9:1 1:9 12.7± 0.34 2.9± 
0.38 
1:9 30.6±1.84 5.0 ± 1.30 
  Religion : H = Hindu ; M = Muslim; O = Others 
 Edu. = Education; Il = Illiterate ; L = Literate 
  SES = Socio-economic status : H = High ; M = Middle ; L = Low income group (according to B G Prasad classification) 
  Occ. = Occupation ; W = Working ; NW = Non-working  
 
Table 3: Symptomatic score in different treatment groups (mean±SE) at time of enrollment 
Symptoms Treatment Groups 
Group A  Group B Group C Group D 
Hot flushes  2±0.37 0.2±0.25 1.8±0.32 2.1±0.27 
Sweating  1.5±0.42 1.9±0.31 1.3±0.36 1.3±0.3 
Dizziness 0.4±0.22 0.4±0.22 0.4±0.26 0.2±0.2 
Anxiety  0.3±0.21 0.3±0.21 0.2±0.13 0.3±0.21 
Insomnia  1.6±0.30 1.6±0.16  1.6±0.37 1.6±0.30 
Depression 1.2±0.33 1±0.29 0.8±0.32 0.4±0.26 
Loss of libido 1.1±0.23 1.3±0.15 0.8±0.24 0.8±0.24 
Headache 0.8±0.20 0.8±0.24 1.2±0.29 0.7±0.30 
Tiredness 0.4±0.16 0.7±0.21 0.7±0.30 0.7±0.26 
Mood swing 0.8±0.32 0.6±0.30 0.4±0.26 0.6±0.26 
Irritability  0.6±0.26 0.9±0.27 0.6±0.26 0.4±0.22 
Nervousness 0.6 ± 0.30 0.8±0.32 0.8±0.29 0.6±0.30 
Tendency to be ill 0.6±0.26 0.8±0.29 0.6±0.22 0.6±0.30 
Osteoarticluar pain 1.15±0.26 1.5±0.22 1.3±0.26 1.1±0.23 
Dyspareunia  0.7±0.21 1±0.21 0.5±0.22 0.8±0.29 
 
 
 
 
Treatment Groups Group A 
n = 10 
Group B 
n = 10 
Group C 
 n = 10 
Group D 
n = 10 
Perimenopause  1 0 4 5 
Natural menopause 4 4 4 4 
Surgical Menopause 5 6 2 1 
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At the onset of study symptoms encountered were comparable in all the 4 groups 
and the difference was not significant (Table 3). Table 4 depicts reduction in 
symptomatic score over 3 months period between the treatment groups. At the end 
of 3 months there was significant decrease in symptomatic score (p< 0.01) for 
most of the symptoms in groups A and B except dizziness, anxiety, tiredness and 
nervousness. In group B mood disorders, loss of libido, dyspareunia and 
osteoarticular pain were better relieved when compared to group Although the 
difference was not significant. Improvement in symptoms in both the groups was 
observed even as early as 1 month follow up and improvement was maintained and 
further improved thereafter.  
In groups C and D significant improvement was observed in hot flushes, sweating 
and insomnia (p < 0.05) but the improvement was much less as compared to 
groups A and B (p < 0.01). Significant improvement was observed in headache in 
group C and dyspareunia in group D. Most of these improvements were observed 
at around 3 months of therapy. There was no statistically significant difference in 
improvement of symptoms in between groups A and B and in between groups C 
and D.  
Comparative analysis of groups A and B with groups C and D reveals statistically 
significant difference in each symptomatic score which were significantly 
decreased at 1 month and 3 months of follow up visit in groups A and B   (p<0.01) 
(Table 4). 
 
Table 4: Comparison of symptomatic improvement in different treatment groups as assessed by symptomatic score (mean±SE) at 1and3 months of follow up.  
 
Symptoms 
Treatment Groups 
Group A Group  B Group C Group D 
 1 month 3 months 1 month 3 months 1month 3months 1month 3months 
Hot flushes  1.20±0.25*# 0.50±0.17!# 1.4±0.22*# 0.8± 0.2!# 1.7±0.28 1.4 ± 0.30* 2.1±0.27 1.4± 0.22* 
Sweating  0.9 ± 0.28*# 0.4 ± 0.16*# 1.6 ± 0.26 0.9± 0.23*# 1.3±0.36 0.9 ± 0.27* 1.3±0.3 1.2 ± 0.29* 
Dizziness 0.4 ± 0.22 0.2 ± 0.3 0.4 ± 0.22 0.1 ± 0.1 0.4±0.26 0.4 ± 0.26 0.2±0.2 0.2 ± 0.2 
Anxiety  0.2 ± 0.13 0.1 ± 0.1 0.3±0.21 0.2 ± 0.13 0.2± 0.13 0.2 ± 0.13 0.3±0.21 0.2 ± 0.2 
Insomnia  1.1 ± 0.23*# 0.5 ± 0.16*# 1.1 ± 0.17*# 0.6±0.16*# 1.6±0.37 1.2 ± 0.32* 1.6±0.30 1.4± 0.30* 
Depression 0.8 ± 0.24*# 0.5 ± 0.17*# 1±0.29 0.6 ± 0.16*# 0.8±0.32 0.7 ± 0.30 0.4±0.26 0.3 ± 0.21 
Loss of libido 0.9 ± 0.18 0.4 ± 0.16*# 0.9±0.15 0.4 ± 0.16*# 0.8±0.24 0.7 ± 0.21 0.8±0.24 0.8±0.24 
Headache 0.6 ± 0.16 0.2 ± 0.13*# 0.8 ± 0.24 0.2± 0.13*# 1.2± 0.29 0.8 ± 0.24* 0.6±0.26 0.5 ± 0.22 
Tiredness 0.4±0.16 0.1 ± 0.1 0.7 ± 0.21 0.5 ± 0.16 0.7±0.30 0.6 ± 0.26 0.7±0.26 0.6 ± 0.22 
Mood swing 0.5 ± 0.22 0.4 ± 0.16 0.4 ± 0.22 0.2± 0.15*# 0.4±0.26 0.4±0.26 0.6±0.26 0.5  ± 0.22 
Irritability  0.6 ± 0.26 0.2 ± 0.13*# 0.9±0.27 0.4± 0.16*# 0.6±0.26 0.5 ± 0.22 0.4±0.22 0.2  ± 0.13  
Nervousness 0.4 ± 0.22 0.3 ± 0.15 0.6 ± 0.26 0.4 ± 0.16 0.8±0.29 0.7 ± 0.26 0.6±0.30 0.6±0.30 
Tendency to be ill 0.5 ± 0.22 0.3 ± 0.15 0.7 ± 0.26 0.3 ± 0.15*# 0.6±0.22 0.4 ± 0.16 0.6±0.30 0.5 ± 0.26 
Osteoarticluar pain 1.1 ± 0.23 0.6 ± 0.16*# 1.3 ± 0.21 0.5 ± 0.16*# 1.3±0.26 1 ± 0.25 1.1±0.23 1 ± 0.25 
Dyspareunia  0.6 ± 0.16 0.3 ± 0.15*# 0.9 ± 0.17 0.5 ± 0.16*# 0.5 ± 0.22 0.4 ± 0.22 0.8±0.29 0.6 ± 0.26* 
* = p < 0.05 vs  0 day value in the same group, ! = p < 0.01 vs  0 day value in the same group,  = p < 0.01 vs group C,      # = p < 0.01 vs group D 
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Table 5 shows adverse effects encountered in different 
groups during follow up visits. Adverse effects were 
more common among the patients who received the 
hormonal treatment. Most common adverse effect 
reported was irregular breakthrough vaginal bleeding 
which was seen in 3 patients of group A out of the 5 
nonhystrectomised patients. Next in order was GI 
upset which was seen in approximately 1% of the total 
enrolled women. Besides these there were few others 
but all these reported adverse effects were mild and 
tolerable and none of the patient withdrew from the 
study due to adverse effects, at any time of the study 
period.
 
Table 5:  Adverse drug effects reported by number of patients in different treatment groups 
Reported events Group A 
n = 10 
Group B 
n = 10 
Group C 
n = 10 
Group D 
n = 10 
Bleeding 3 0 0 0 
Headache  1 1 0 0 
Nausea  3 1 1 0 
Hirsutism 0 1 0 0 
GI upset 0 1 2 0 
 
Haemoglobin, blood sugar, lipid profile, urine analysis 
did not show any significant change at the end of the 
study. Ultrasonographic reports were normal both at 
the start of the treatment and at the end of study and no 
patients showed any detectable endometrial 
proliferation. Mammography scans were done at the 
end of study only in the women of groups A and B and 
were found to be normal.  
DISCUSSION 
Despite the fact that most of the women in some way 
face the short- and long-term health consequences of 
menopausal estrogen deficiency, many avoid HRT, 
primarily because of concerns related to safety and 
side effects. To date, even clinicians have been limited 
in their ability to address these concerns and besides 
this there is dilemma related with the use of alternative 
medications because of the limited safety and efficacy 
data.  
This study shows that short course HRT is an 
efficacious modality with few tolerable side effects, 
for the management of menopausal symptoms. This is 
in accordance with the various earlier studies 
5,8,9
. 
Reanalysis of the earlier published studies ( WHI, 
HERS) including the Kronos Early Estrogen 
Prevention Study and Danish Osteoporosis Prevention 
Study suggest that HRT is primarily beneficial when 
initiated in younger women closer to the onset of 
menopause, but harmful when initiated later in life or 
further from the onset of menopause 
6,7
. 
According to the present study Tibolone and 
conventional HRT have similar efficacy in alleviating 
most of the menopausal symptoms. The only 
difference observed was in symptoms like mood 
swings, loss of libido, dyspareunia and osteoarticular 
pain which were better relived in group B as compared 
to group A, although the difference was not 
statistically significant. A double blind comparative 
study conducted in 437 postmenopausal women with 
climacteric complaints done over a period of one year 
showed that both tibolone and combined estrogen 
progesterone therapy reduced climacteric symptoms to 
a similar extent
10
. In another comparative study done 
in 129 postmenopausal women, tibolone was more 
effective in improving the mood disorders and loss of 
libido after six months of therapy
8
. The reason for 
mood elevating effect of tibolone may be an increase 
in plasma endorphin levels
11
. Usually menopause is 
associated with reduction in endorphin levels, which is 
believed to be involved in the pathogenesis of mood 
disorders. The benefit in loss of libido observed in 
group B could be due to its androgenic effects
11
. 
Therefore this study confirms in many respects the 
results of other  previous  comparative studies. 
 In the non-hormonal alternative groups, the study 
demonstrates significant improvement in hot flushes, 
sweating and insomnia with isoflavone and vitamin E 
treatment. The use of isoflavone to modify the 
symptoms of estrogen deficiency has been addressed 
in small studies with conflicting results regarding the 
efficacy. In a metaanalysis of 14 trials, 11 showed 
significant improvement in the isoflavone group 
compared to placebo while 3 trials failed to show any 
benefit
12
. Epidemiological studies have also shown 
that the population in which soy isoflavone intake is 
higher, have lesser prevalence of vasomotor 
symptoms
13
. Possible explanation for this reduction is 
estrogenic component of isoflavone. Besides, it also 
has antioxidant effect which may have beneficial 
effect in slowing the degeneration of graffian follicles 
which will prevent the abrupt fall in estrogen levels
14
. 
The beneficial effects of isoflavone observed in our 
study can be attributed to the similar reasons as 
mentioned above.    
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As with isoflavone, there are very few studies which 
have addressed vitamin E for the control of 
menopausal symptoms. In one study involving 120 
patients vitamin E in the dose of 800 IU was more 
effective than placebo (32% vs 29%; p <0.05) for the 
control of menopausal vasomotor symptoms
15
. In yet 
another placebo controlled study of vitamin E showed 
greater reduction of hot flushes than observed with 
placebo ( 30% vs 25 %) over basal symptoms
16
. The 
mechanism for small reduction of hot flushes is 
unknown apart from possible placebo effects. Most of 
the studies have used 800 I.U of vitamin E but even by 
use of 400 IU for 12 weeks have also led to significant 
improvement in clinical outcome
17
. The reason for this 
meagre beneficial effect have not been yet elucidated 
apart from the possible placebo effect and hence 
further studies are needed.  
CONCLUSIONS 
The above results suggest that conventional HRT and 
tibolone are very efficacious with only few tolerable 
side effects when used for short period. Despite the 
fact that alternative treatments like isoflavone and 
vitamin E are less efficacious as that of conventional 
HRT and tibolone but can serve as a satisfactory 
treatment option when either hormonal therapy is 
contraindicated or there is risk associated with 
hormonal use or when woman is not in favour of 
hormonal treatment.  
Limitations: The present study has certain limitations 
such as short duration and small sample size so, 
caution should be exercised while extrapolating the 
results. 
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